Background-A deficiency of muscle LIM protein results in dilated cardiomyopathy, but the function of other LIM proteins in the heart has not been assessed previously. We have characterized the expression and function of FHL2, a heart-specific member of the LIM domain gene family. Methods and Results-Expression of FHL2 mRNA and protein was examined by Northern blot, in situ hybridization, and
T he LIM protein superfamily comprises transcription factors, protein kinases, and cytoskeletal proteins that are involved in a wide range of cellular functions, including cell lineage determination, differentiation, focal adhesion, and signal transduction. 1, 2 The signature LIM motif is defined by the presence of 1 or multiple consensus sequence motifs (CX 2 CX 17-19 HX 2 C 2 X 2 CX 16 -20 CX 2 C), and LIM proteins can be subdivided into several subclasses based on the number of LIM motifs and the presence or absence of additional motifs in the protein. LIM-homeodomain proteins include both LIM motifs and a homeobox region, and several are known to be essential for development of skeletal, endocrine, or neuronal structures in vertebrates. [3] [4] [5] LIM-only (LMO) proteins lack a homeodomain and contain variable numbers of LIM motifs. An LMO protein called muscle LIM protein (MLP) is a positive regulator of skeletal muscle differentiation 6, 7 and is required for maintenance of normal structure and function of the myocardium. Mice deficient in this LMO protein develop dilated cardiomyopathy during postnatal life. 8 A specific subclass of LMO proteins contain four and a half LIM motifs and are designated as FHL proteins. Human FHL2, originally known as DRAL (Down-Regulated in Rhabdomyosarcoma LIM protein), was first identified by subtractive hybrid-ization of normal myoblasts versus a rhabdomyosarcoma cell line. 9 We isolated a murine homologue of FHL2 from a cardiac cDNA library in a screen for proteins interacting with myocyte nuclear factor (MNF), a forkhead/winged helix transcription factor expressed in developing heart and skeletal muscles and in myogenic progenitor cells (satellite cells) of adult mice. 10 -12 In this report, we describe the temporal and spatial pattern of FHL2 expression pattern throughout mouse development. FHL2 expression is evident in the earliest identifiable cardiac precursor cells of the embryo and is restricted primarily to cardiomyocytes during fetal and adult life. Analysis of homozygous knockout mice shows that FHL2 is not required for normal cardiac development. Cardiac mass is increased more, however, in adult mice devoid of FHL2 than in wild-type littermates after administration of the ␤-adrenergic agonist isoproterenol. We conclude that the FHL2 is an early and persistent marker of the cardiomyocyte lineage in the mouse and can modify responses to certain stresses in the adult heart.
Methods

Cloning of FHL2 Gene and Construction of the Targeting Vector
FHL2 cDNA was isolated from a murine cardiac library in a yeast 2-hybrid screen using MNF 10 -12 as bait. Mouse genomic DNA encoding FHL2 was isolated from a 129SVJ genomic P1 library (Stratagene) by use of probes based on the cDNA sequence. The FHL2 LacZ/neo targeting vector was constructed in pBluescript (Stratagene) to include 1.3 kb and 8 kb of homologous sequence regions located 5Ј and 3Ј, respectively, to the region of the FHL2 gene altered by homologous recombination. In the mutant FHL2 allele, protein coding sequences from exon 2 (E2) of the native gene, including the translation initiation codon ATG, the N-terminal half LIM motif, part of the LIM1 domain, and 0.5 kb of intronic sequence downstream of E2 are replaced with a LacZ reporter gene and a neo resistance cassette. LoxP sites flank the neo cassette. The final construct was verified by restriction analysis and partial sequencing.
Generation of FHL2 Knockout Mice
Southern blot analysis performed on DNA isolated from neomycinresistant ES clones showed that 8 of 500 ES clones had undergone homologous recombination of the targeting vector into the FHL2 locus. Three targeted ES clones transmitted the mutant allele through the germ line and generated FHL2 LacZ/neo heterozygote (FHL2 ϩ/Ϫ ) animals, which were crossed to generate FHL2 Ϫ/Ϫ mice. The phenotypic consequences of FHL2 deficiency were equivalent in offspring of the 3 separately derived lines of transgenic mice.
Mouse Embryo Analysis
Embryonic stage (days postcoitum) was estimated by timed pregnancies and somite counts. The embryos and decidua were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Expression of ␤-galactosidase in murine embryos was assessed as previously described. 13
Expression of FHL2 mRNA and Protein
RNA was isolated from adult or fetal tissues, and Northern blots were prepared and probed as previously described. 14 Proteins (10 g/lane) were separated by electrophoresis through a 12% SDSpolyacrylamide gel, transferred to nylon filters, and probed with a rabbit polyclonal antibody against FHL2. In situ hybridizations were performed as previously described. 15
Chronic Infusion of Isoproterenol
Seven-day osmotic minipumps (Alzet, model 2001) were loaded with 0.2 mL of isoproterenol (28 mg/mL per 25 g body weight) and implanted into the subcutaneous space of 6-to 7-month-old mice. After 10 days, hearts were harvested, weighed, and analyzed histologically.
Statistical Analysis
The hypertrophic responses to chronic isoproterenol administration in FHL2 knockout and wild-type mice were compared by the Wilcoxon rank sum test.
Results
Conservation of Human and Mouse FHL2 cDNA Sequences
The cloned FHL2 cDNA encodes a 279-amino-acid protein that has 91% homology to the human FHL2 protein 9,16,17 ( Figure  1A ). The FHL motifs are arrayed in tandem and separated by 8 amino acid linkers that are conserved between human and mouse FHL2 proteins, as well as in FHL1/SLIM1 and FHL3/ SLIM2. 18, 19 A list of currently known FHL and cysteine-rich proteins (CRP proteins) is provided in Figure 1B .
Expression of FHL2 in Adult Tissues
Expression of FHL2 mRNA in adult mice is detected by Northern blot analysis only in heart, and not in skeletal muscle, brain, spleen, liver, kidney, or testis ( Figure 2A) . A rabbit polyclonal antibody raised against recombinant murine FHL2 protein detects a 33-kDa protein, approximately the size predicted from the cDNA sequence, in extracts of adult mouse heart ( Figure 2B ), with trace levels also evident in stomach. In situ hybridization performed with a 35 S-labeled antisense FHL2 probe on transverse sections of adult cardiac ventricles ( Figure 2C and 2D) demonstrates the presence of FHL2 transcripts within cardiomyocytes throughout the ventricular free walls and prominently in the septum. In contrast, no FHL2 mRNA is present within cells of the coronary vasculature (arrows in Figure 2D ).
FHL2 Is an Early and Persistent Marker of the Cardiomyocyte Lineage
FHL2 mRNA can be detected by Northern blot analysis as early as embryonic day 7 ( Figure 3A ) and continues to be detected in later-stage embryos. In situ hybridization ( Figure  3B through 3E) showed that FHL2 transcripts are present during heart development; in the common atrium, primitive ventricle and bulbus cordis of the looping heart tube at E9.5; in the common atrium, the developing septal primordium, and compact and trabecular components of the bulbus cordis at E10.5; in the atria and ventricular free walls but not the atrioventricular cushion at E12.5; and in the myocardium, including the intraventricular septum, but not the outflow tract or atrioventricular cushions at E14.5. FHL2 expression also can be detected in extracardiac tissues at certain stages of development ( Figure 3B through 3E). From E9.5 to E12.5, FHL2 is expressed in undifferentiated cells of the head and gut mesenchyme, within the endothelium of the dorsal aorta and branchial arch arteries, and in a narrow subepithelial zone of the developing mid gut and bronchi. At E14.5, FHL2 expression is evident in the wall of the gut, in the urogenital sinus and associated umbilical artery, and in mesenchyme surrounding the spinal cord.
The earliest stages of cardiac development in vertebrates can be defined by the expression of the homeodomain protein Nkx2.5/Csx 20,21 in precardiac mesoderm. At ϷE7.5, Nkx2.5 is expressed in cardiac progenitor cells located at the anterior and lateral regions of the embryo, which fuse in the midline to form the cardiac crescent. 13, [22] [23] [24] Whole-mount in situ hybridizations performed on littermate embryos ( Figure 4) show that FHL2 and Nkx2.5 transcripts are colocalized within precardiac mesoderm of embryos at the early headfold stage (ϷE7.5) and at subsequent stages of heart development.
Expression of a ␤-Galactosidase (LacZ) Reporter Gene Inserted Into the Mouse FHL2 Gene Locus
Heterozygous FHL2 LacZ/neo embryos were generated by homologous recombination of a targeting vector into the FHL2 locus ( Figure 5 ) and were analyzed for ␤-galactosidase activity at stages from E3.5 through E9.5 ( Figure 6 ). In early embryos before heart development (E3.5 to E6.5), transcription of the LacZ transgene is evident in extraembryonic tissues, such as polar trophectoderm around the blastocoelic cavity of the intact blastocyst ( Figure 6A ), and in extraembryonic ectoderm at the onset of gastrulation ( Figure 6B ). FHL2 LacZ/neo expression is observed in the chorion (part of the future placenta) of the extraembryonic tissue and in the chorioallantoic placenta at E9.5 ( Figure 6A and 6B) . At E7.5, ␤-galactosidase activity is detected in the cardiac crescent, corroborating results obtained with whole-mount in situ hybridizations (Figure 4 , E7.5). At later stages of heart development, strong FHL2 LacZ/neo expression continues in developing cardiomyocytes, but no expression is seen in the endocardium or the bulbotruncal junction region of the outflow tract of the primitive heart. Weak FHL2 LacZ/neo expression can be detected in the stomach, fat pads, and spleen, but no detectable levels of LacZ expression are observed in brain, lung, liver, and skeletal muscle (data not shown).
Normal Cardiovascular Development in Mice Lacking FHL2
The gene-targeting strategy used to insert a LacZ reporter gene into the FHL2 locus was designed also to produce a null allele by eliminating E2 of the FHL2 gene ( Figure 5 ). Genotyping revealed wild-type (FHL2 ϩ/ϩ ), heterozygous (FHL2 ϩ/Ϫ ), and homozygous (FHL2 Ϫ/Ϫ ) offspring close to the mendelian prediction, indicating no survival disadvantage for embryos lacking FHL2. The null state was confirmed by the absence of FHL2 mRNA and protein as assessed by Northern ( Figure 5C ) and Western ( Figure 5D ) blot analyses of hearts from FHL2 Ϫ/Ϫ mice. Gross and microscopic anatomy of hearts from adult mice without FHL2 were normal.
Hypertrophic Responses to ␤-Adrenergic Stimulation
Osmotic minipumps loaded with 0.2 mL of isoproterenol (28 mg/mL per 25 g body weight) were implanted into mice to subject these animals to the stress of sustained ␤-adrenergic stimulation. This stimulus is known to provoke cardiac hypertrophy in wild-type mice, 25 and we confirmed this finding in wild-type littermates of FHL2 Ϫ/Ϫ animals on harvesting the hearts 10 days after implantation. We noted, however, that the hypertrophic response of hearts from mice lacking FHL2 was exaggerated above that in wild-type animals ( Figure 7A ). As shown in Figure 7B , in the absence of drug treatment, there was no apparent difference in heart-weight/body-weight ratios among 12 FHL2 Ϫ/Ϫ mice (5.5Ϯ0.3 mg/g) compared with an equal number of FHL2 ϩ/ϩ littermates (5.7Ϯ0.3 mg/g). After isoproterenol, however, heart-weight/body-weight ratios in 12 FHL2 Ϫ/Ϫ mice (8.7Ϯ0.4 mg/g) were greater than those of FHL2 ϩ/ϩ littermates (6.9Ϯ0.2 mg/g) (PϽ0. 01). The increase in mean cardiac mass of FHL2 Ϫ/Ϫ mice was 58%, compared with 20% for wild-type animals. This exaggerated hypertrophic response in FHL2 Ϫ/Ϫ mice was associated with a greater activation in expression of atrial natriuretic factor, a wellcharacterized molecular marker of cardiac hypertrophy (Figure 7C ).
Discussion
There are 2 principal findings of this study. First, the LIM protein FHL2 is an early and persistent marker of cells within the cardiomyocyte lineage. FHL2 is expressed in the earliest identifiable myocardial progenitor cells of the cardiac crescent in a pattern that resembles that of the homeodomain protein Nkx2.5. FHL2 continues to be expressed selectively in cells of the atrial and ventricular myocardium at later stages of cardiac development and in the adult heart. Like Nkx2.5, FHL2 is not restricted entirely to the heart, but expression in other fetal and adult tissues is transient and/or minimal compared with the strong and persistent expression within the myocardium. The second major finding is that although FHL2 is not required for normal cardiovascular development, FHL2 modifies responses of the adult myocardium to certain stresses. Specifically, we observed an exaggerated hypertrophic response to the ␤-adrenergic receptor agonist isoproterenol in FHL2 Ϫ/Ϫ mice.
Other LIM proteins are expressed in the heart, but none exhibit the temporal and spatial pattern of expression we report here for FHL2. The LMO protein MLP is highly enriched in adult cardiomyocytes, but the earliest reported onset of MLP expression during embryonic life (E9) 26 follows that of FHL2 (E7.5). In addition, MLP is expressed prominently in somites and developing skeletal muscles, 6 whereas FHL2 expression is not detected in these tissues. The LMO proteins CRP1 and CRP2, which are more closely related to MLP than to FHL2 (see Figure 1B) , are expressed in the developing heart, but in a pattern that differs from that of FHL2. CRP1 expression is detected in both atria and ventricles at E9.5 but, unlike FHL2, is also abundant in vascular and nonvascular smooth muscle cells of the outflow tract. 26 This pattern differs from both FHL2 and MLP, the expression of which within the heart is restricted to cardiomyocytes. FHL1/SLIM1 and FHL3/SLIM2 are closely related structurally to FHL2 and are expressed in skeletal muscles and heart. 16, 18, 19, [27] [28] [29] [30] Although FHL2 exhibits a greater degree of cardiac specificity than other known LIM proteins, it is possible that related FHL proteins can substitute for developmental functions of FHL2 within in the developing heart.
The present study did not address biochemical functions of FHL2, but the literature provides several interesting leads for future investigations. The FHL protein ACT functions as a transcriptional coactivator with CREM and CREB proteins. 31 FHL2 itself was recently shown to function as a coactivator in association with androgen receptors. 32 It will be interesting to determine whether FHL2 collaborates with nuclear receptors or CREM/CREB proteins in the myocardium, particularly because transgenic mice expressing a dominant negative form of CREB develop dilated cardiomyopathy. 33 Our own preliminary data showing a physical association between FHL2and DNA-binding MNF proteins 10 Ϫ12 also lend credence to the speculation that FHL2 may be a transcriptional modulator in the heart.
Among the set of transcriptional regulators known to have an important role in cardiac development, FHL2 expression most closely parallels that of the homeodomain protein Nkx2.5. The colocalized expression of FHL2 and Nkx2.5 suggests either that these 2 genes are responding to a common set of upstream regulators or that one may serve to control the other. In either case, detailed examination of promoter and enhancer elements from the FHL2 gene, in parallel with similar studies of Nkx2.5 gene regulation, may shed light on transcriptional events pertinent to the earliest steps of cardiomyocyte determination.
Finally, the observation that FHL2 Ϫ/Ϫ mice have an exaggerated response to the hypertrophic effects of isoproterenol suggests that FHL2 interacts with downstream effectors of ␤-adrenergic receptor signaling in the myocardium or with proteins shared among different hypertrophic signaling pathways. As a gene that is not required for normal development but is capable of modifying cardiac responses to environmental stress, it is possible that allelic variants of the FHL2 gene may be present within human populations and influence the natural history of cardiovascular diseases in a clinical setting. . Hypertrophic response to ␤-adrenergic stimulation is augmented in mice lacking FHL2. A, Trichrome-stained histological sections of adult heart from untreated or isoproterenol-treated FHL2 ϩ/ϩ and FLH2 Ϫ/Ϫ mice. Multifocal areas of myocardial fibrosis (blue) are evident within left ventricular free wall of isoproterenol-treated FHL2 Ϫ/Ϫ animal. B, Heart-weight-to-body-weight ratios are increased by infusion of isoproterenol from osmotic minipumps in both wildtype (FHL2 ϩ/ϩ ) and mutant (FHL2 Ϫ/Ϫ ) mice. Magnitude of increase in FHL2 Ϫ/Ϫ animals (59%), however, was greater than that observed in FHL2 ϩ/ϩ mice (20%). C, Northern blot analysis showing increased expression of hypertrophic marker atrial natriuretic factor in mice lacking FHL2 compared with wild-type mice after isoproterenol treatment.
